PROPOSED QUALITY-CONTROL GUIDELINES FOR ANTIMICROBIAL SUSCEPTIBILITY TESTS USING TILMICOSIN

被引：6

作者：

SHRYOCK, TR ^{[1
]}

WHITE, DW ^{[1
]}

WERNER, CS ^{[1
]}

STAPLES, JM ^{[1
]}

机构：

[1] CAVL INC,AMARILLO,TX 79118

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 1995年 / 33卷 / 02期

关键词：

D O I：

10.1128/JCM.33.2.331-335.1995

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Quality control guidelines for tilmicosin, a novel veterinary-use-only macrolide, were developed in a multilaboratory study according to established National Committee for Clinical Laboratory Standards (NCCLS) procedures (M23-T2), Tilmicosin was incorporated into Sensititre plates far broth microdilution endpoint testing and into two lots of 15-mu g disks for Kirby-Bauer agar disk diffusion testing. One common lot and five unique lots of Mueller-Hinton media were used, (Broth,vas cation adjusted, and agar was supplemented with 5% defibrinated sheep blood.) Bacteria used for reference strains included Pasteurella haemolytica 128K, Pasteurella multocida ATCC 43137, and Staphylococcus aureus ATCC 29213 (microdilution) and ATCC 25923 (disk), Replicate tests were conducted. Disk diffusion and broth microdilution quality control ranges are proposed,

引用

页码：331 / 335

页数：5

共 14 条

[1]

[Anonymous], 1993, M7A3 NAT COMM CLIN L

[2] QUALITY-CONTROL GUIDELINES FOR CEFDINIR, CEFEPIME, CEFETAMET, CEFMETAZOLE, CEFPODOXIME, CEFPROZIL, AND CLINAFLOXACIN (CI-960) FOR VARIOUS NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS SUSCEPTIBILITY TESTING METHODS [J].